Adele Stronach

Dynamic Clinical Trials Coordinator with a proven track record at Cancer Services Trials Unit, excelling in regulatory compliance and participant recruitment. Adept at fostering collaboration and maintaining high standards in data collection and quality assurance, I leverage strong analytical thinking and effective communication to drive successful oncology research outcomes.

• Dr Johannes Zuber, Vienna, Austria, Creating novel mouse models
• Prof Andrew Wei, Developing AML stem cell lines
• Dr Stefan Glaser and Andreas Strasser (WEHI), 01/01/10, Transduction of MCL-1 in human AML patient samples

• Resilience program, Shell Australia, 01/01/13
• The Global Research Ethics and Integrity Module, The University of Melbourne, 8 week course, 01/01/11
• Research Governance Program, Peter MacCallum Cancer Centre, 01/01/11-12/31/14
• Conducting Clinical Research training course- Essential GCP, 01/01/17
• ICH-GCP, 01/01/18-current
• Safe transport of Infectious Substance by Air Course, 01/01/17 (2 yearly)- current
• First aid course, 01/01/18-current

• Lifetime Golden Key Honours Society, 01/01/08
• Haematology Society of Australia and New Zealand (HSANZ)
• Australian Society of Medical Research (ASMR)
• ASN events
• The European Association for Cancer Research (EACR)
• Cancer Therapeutics Cooperative Research Centre
• International Society of Experimental Haematology (ISEH)
• ALLG society

Date of Birth: 06/14/84

Dr Fiona Collier, Deputy Laboratory Director, Barwon Biomedical Research, Geelong Hospital, FIONAC@BarwonHealth.org.au, 03 5226 7027

• 26th Lorne Cancer Conference Best Poster Prize, 01/01/14
• Cancer Therapeutics CTx Travel Scholarship, 01/01/13
• Melbourne Abroad Travel Scholarship (MATS), 01/01/13
• Australian PG Award scholarship, 01/01/11-12/31/14
• Arrow Hawkesbury Bone Marrow Transplant scholarship, 01/01/11-12/31/14
• Invited into the Golden Key International Honours society exclusive top 15% of students (Deakin University chapter), 01/01/07

· Guest speaker at Peter MacCallum “Walk to end women’s cancers”

· Guest speaker at The Cancer Council Relay For life Geelong

· Guest speaker at Light the Night leukaemia foundation in Geelong

· Organizing committee for ASMR student symposium

· President of the Peter MacCallum student representative committee

· Guest speaker at schools during science week; Ali Currung School in the Northern Territory and other Primary   

  Schools

· Fundraising and personal participation in; Weekend to End Women’s cancer, Cancer Council Relay for Life, Angel

  Flight, and Red Kite

· Fundraising and event organisation assistant Heart Kids

· Team managers for children’s sports and family and friends school committee member.

1. The CDK9 inhibitor Dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemia. Baker AJ, Gregory GP, Verbrugge I, Kats L, Hilton JJ, Vidacs E, Lee EM, Lock RB, Zuber J, Shortt J, Johnstone RW. Cancer Research. 2016 March 1; 76(5):1158-69

2. CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. Gregory, G P, Hogg, S J, Kats, L M, Vidacs, E, Baker, A J, Gilan, O, Lefebure, M, Martin, B P, Dawson, M A, Johnstone, R W, Shortt, J. Leukemia. 2015 Jun;29(6):1437-41

3. Differentiation therapy for the treatment of t(8;21) acute myeloid leukaemia using histone deacetylase inhibitors. Bots M, Verbrugge I, Martin BP, Salmon JM, Ghisi M, Baker A, Stanley K, Shortt J, Ossenkoppele GJ, Zuber J, Rappaport AR, Atadja P, Lowe SW, Johnstone RW. Blood. 2014 Feb 27;123(9):1341-52.

4. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Shortt J, Martin BP, Newbold A, Hannan KM, Devlin JR, Baker AJ, Ralli R, Cullinane C, Schmitt CA, Reimann M, Hall MN, Wall M, Hannan RD, Pearson RB, McArthur GA, Johnstone RW. Blood. 2013 Apr 11;121(15):2964-74.

5. Targeting acute myeloid leukaemia by dual inhibition of PI3K signalling and Cdk9-mediated Mcl-1 transcription. Thomas D, Powell JA, Vergez F, Segal DH, Nguyen NY, Baker A, Teh TC, Barry EF, Sarry JE, Lee EM, Nero TL, Jabbour AM, Pomilio G, Green BD, Manenti S, Glaser SP, Parker MW, Lopez AF, Ekert PG, Lock RB, Huang DC, Nilsson SK, Récher C, Wei AH, Guthridge MA. Blood. 2013 Aug 1;122(5):738-48.

6. RTKN2 Induces NF-KappaB Dependent Resistance to Intrinsic Apoptosis in HEK Cells and Regulates BCL-2 Genes in Human CD4+Lymphocytes. Collier, FM., Loving, A, Baker, AJ., McLeod, J, Walder, K, Kirkland, MA. Journal of Cell death. 2009: 2;9-23

7. Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.

Hein N, Cameron DP, Hannan KM, Nguyen NN, Fong CY, Sornkom J, Wall M, Pavy M, Cullinane C, Diesch J, Devlin JR, George AJ, Sanij E, Quin J, Poortinga G, Verbrugge I, Baker A, Drygin D, Harrison SJ, Rozario JD, Powell JA, Pitson SM, Zuber J, Johnstone RW, Dawson MA, Guthridge MA, Wei A, McArthur GA, Pearson RB, Hannan RD. Blood 2017 May 25;129(21):2882-2895.